Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with platinum-based chemotherapy then maintenance pembrolizumab within its marketing authorisation for the treatment of advanced or recurrent endometrial cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Awaiting decision
- Process:
- STA Standard
- ID number:
- 6381
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Warwick Evidence, Warwick Medical School, University of Warwick
Stakeholders
- Companies sponsors
- Merck Sharp & Dohme (pembrolizumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Peaches Womb Cancer Trust
- Professional groups
- Association of Anaesthetists
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- Accord (carboplatin, paclitaxel, cisplatin, doxorubicin) CAU not signed (not participating)
- Alliance Healthcare (cyclophosphamide, paclitaxel) CAU not signed (not participating)
- Bausch & Lomb (megestrol acetate) CAU not signed (not participating)
- Baxter Healthcare (cyclophosphamide) CAU not signed (not participating)
- Bristol Myers Squibb Pharmaceuticals (paclitaxel) CAU not signed (not participating)
- Consilient Health (carboplatin) CAU not signed (not participating)
- Fresenius Kabi (carboplatin, paclitaxel) CAU not signed (not participating)
- Hospira UK (carboplatin, paclitaxel) CAU not signed (not participating)
- Johnson & Johnson Innovative Medicine (doxorubicin) CAU not signed (not participating)
- Medac GmbH (doxorubicin) CAU not signed (not participating)
- Novartis (cisplatin, cyclophosphamide) CAU not signed (not participating)
- Pfizer (carboplatin, paclitaxel, cisplatin, doxorubicin, medroxyprogesterone acetate) CAU not signed (not participating)
- Sandoz (cyclophosphamide) CAU not signed (not participating)
- Seacross Pharmaceuticals (paclitaxel, doxorubicin) CAU not signed (not participating)
- Teva UK (carboplatin, paclitaxel) CAU not signed (not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Government
- Welsh Health Specialised Services Committee
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 August 2025 - 07 August 2025 | Final draft guidance |
| 06 May 2025 | Declaration of interests |
| 24 March 2025 - 14 April 2025 | Draft guidance: 1 |
| 04 February 2025 | Committee meeting: 1 |
| 04 February 2025 | Declaration of interests |
| 08 July 2024 | Invitation to participate |
| 20 May 2024 - 18 June 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6381 |
| 20 May 2024 | In progress. Scoping commencing |
| 24 November 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 24 November 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual